-24 days o l d ( d ) . Normoxic iambs were g i v e n 1 and 10 ug/kg w i t h r e c o v e r y t i m e b e t w e e n d o s e s .
v e n t i l a t e d w i t h 13% O2 and g i v e n t h e same d o s e s o f PGD .
We compared $ a of $a, mean systemic a r t e r i a l p r e s s u r e (~a s ; j , and PVR i n lambs <7d and 214d.
C7d
>l4d X I SD; N = normoxia, H = hypoxia; #p < 0.05 from z e r o change.
I n normoxic lambs, 1 N / k g had no e f f e c t on T p a and PVR a t <7d but c a u s e d s i g n i f i c a n t i n c r e a s e s i n 214d a n i m a l s . Ten &kg r a i s e d Fpa and PVR i n b o t h y o u n g e r and o l d e r normoxic lambs. I n hypoxic animals, both doses lowered P p a a n d PVR i n t h e <7d g r o u p , w h i l e i n t h e 214d lambs t h e r e was l i t t l e o r no pulmonary e f f e c t . Pas was s i g n i f i c a n t l y i n c r e a s e d by PGD2 i n a l l groups a t both doses. We c o n c l u d e t h a t t h e pulmonary v a s o d i l a t o r e f f e c t o f PGD2 i n h y p o x i c n e o n a t a l l a m b s d e c r e a s e s with advancing p o s t n a t a l a g e , and t h a t by 14 d a y s , PGD2 i s no l o n g e r a n e f f e c t i v e pulmonary v a s o d i l a t o r .
PHARMACOLOGY OF PANTETHINE IN NEPHROPATHIC CYSTINOSIS
403 Carl T. Wittwer, J e s s G. Thoene U n i v e r s i t y o f Michigan School of Medicine, Department o f P e d i a t r i c s , Ann Arbor, Michigan
Oral D-pantethine ( P I ) a s a source o f cysteamine i n t h e t r e a tment o f nephropathic c y s t i n o s i s was i n v e s t i g a t e d in two c y s t i n ot i c p a t i e n t s who were t r e a t e d with 70-1000 mglkglday PI. WBC cyst i n e , and plasma and u r i n a r y pantothenate (PA) were measured by RIA. Only PA (no PI) was found i n t h e plasma and u r i n e of P I -t r e at e d p a t i e n t s . A f t e r a s i n g l e 30 mg/kg dose, plasma PA l e v e l s a t 0, 114, 112, 1 , 2 , 4 , 8 , and 24 hours were c o n s i s t e n t with an open two compartment model with r a t e c o n s t a n t s o f c a . 0.04/hr f o r e l imination and > l .O/hr f o r d i s t r i b u t i o n . Peak plasma PA (10 nmoljml) occurred a t 2 h r , and t h e apparent volume of d i s t r i b u t i o n was 77 l i t e r s f o r a 49 kg boy. Near l i n e a r i t y with dose was found f o r plasma PA ( r = 0 . 9 7 , s l i g h t concavity upward) and PA e x c r e t i o n ( r = 0.97, s l i g h t concavity downward). Average PA e x c r e t i o n from t h e s l o p e o f t h e l i n e a r r e g r e s s i o n l i n e was only 5% of t h e dose. A t 1000 mglkglday, plasma PA was 180 nmol/ml , 300 times b a s e l i n e .
Increased s t o o l frequency (3-4/day) was t h e only s i g n i f i c a n t s i d e e f f e c t . Plasma c h o l e s t e r o l decreased from 251 t o 204 mgfdl over an 18 day course o f 1000 mglkglday PI, supporting t h i s a g e n t s r o l e a s a hypolipidemic. 50-60% WBC c y s t i n e d e p l e t i o n was achieved. Although PI i s a p p a r e n t l y p a s s i v e l y absorbed and hydrolyzed t o PA and cysteamine i n t h e i n t e s t i n e and/or plasma, l i m i t e d a b s o r p t i o n producing only modest WBC c y s t i n e d e p l e t i o n suggests t h i s a g e n t may not be useful i n t h e t r e a t m e n t o f c y s t i n o s i s . We have previously described the association between maternal Li therapy during pregnancy and fetal macrosomia (Ped Res 17(4): 304A, 1983) . This study reviews t h e records of 241 infants reported t o the Register of Lithium Babies between 1962-1978. All infants were included in calculating mortality statistics. Gestational age (GA), birthweight (BW), sex, Li dose and duration of therapy were analyzed in 180 infants. Premature delivery occurred in 39% of the pregnancies. Mothers of premature infants were treated with higher daily Li doses during t h e 1st and 2nd trimester than mothers of term infants (1.2 + .6 grn vs. .9 2 .5 gm (1st trim.), p ~0 0 1 and 1.0 2 .8 gm vs .8 + .5 gm (2nd trim.), pz.06).
INFANTS O F MOTHERS TREATED WITH LITHIUM (Li) DURING PREGNANCY HAVE AN INCREASED INCIDENCE
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Macrosomia (BW > 90th %tile for GA) was identified in 36% of the infants with a higher frequency in infants born prematurely than in those born a t term (59% vs. 26%). The degree of macrosomia was significantly more pronounced in premature infants than in full term infants (129 + 23 vs.
106 5 18, % mean BW for GA, p<.0001). Perinatal mortality was 8.3% (projected 83 deaths/1000 live births) and included 8 stillbirths. Premature delivery accounted for 42% of the perinatal deaths. This study demonstrates t h a t maternal use of Li (particularly greater than I gram daily in t h e 1st and 2nd trimester) during pregnancy constitutes a significant risk of premature delivery and fetal macrosornia. Prenatal management of these high risk pregnancies should include close monitoring for excessive intrauterine growth and premature labor. The t o c o l y t i c a g e n t R i s used t o prevent premature l a b o r by d i r e c t e f f e c t s ( 6 -a g o n i s t ) upon u t e r i n e smooth muscle. The pharmacology of R i s much l i k e t h e CA epinephrine(EP1)in i t s metaboli c e f f e c t s . Since R i s E P I -l i k e , t h e e f f e c t s on pup adrenal CA c o n t e n t was i n v e s t i g a t e d by d e l i v e r i n g t o t h e Dam pharmacologic R (13.8 mglMZ/hr),by subcutaneous osm,otic mini-pump on days 15-7' g e s t a t i o n . Control Dams were i d e n t i c a l t o R t r e a t e d except pumps contained s a l i n e . On day 21 pups were taken by C-section and adr e n a l~ were immediately processed f o r CA a n a l y s i s by high perform ance l i q u i d chromatography with electrochemical d e t e c t i o n . The EPI was s i g n i f i c a n t l y reduced (428%) i n t h e R t r e a t e d group; no e f f e c t s were-seen i n dopamine(DA)or n o r e p i n e p h r i n e ( N E ) c o n t e n t T The decreased adrenal EPI c o n t e n t i s most l i k e l y due t o e i t h e r displacement of EPI by R and/or an i n h i b i t i o n of EPI s y n t h e s i s .
The mechanism and r a m i f i c a t i o n s of R's e f f e c t on pup adrenal EPI c o n t e n t remain t o be e s t a b l i s h e d .
ENDOCRINOLOGY
ACQUIRED HYPOPITUITARISM AFTER REYE'S SYNDROME. Indu . Growth f a i l u r e a f t e r Reye's Syndrome was s t u d i e d i n a 14 y e a r old w h i t e male. He had Reye's Syndrome a t age t e n y e a r s and a l s o had l o s s of v i s i o n , which l a t e r improved c o n s i d e r a b l y i n t h e r i g h t eye. A f t e r recovery from Reye's Syndrome, he had no inc r e a s e i n l i n e a r growth d u r i n g t h e following f o u r y e a r s . From 75th p e r c e n t i l e , h i s h e i g h t dropped t o below 5 t h p e r c e n t i l e . His s e x u a l maturation was i n Tanner S t a g e I and funduscopic examinat i o n r e v e a l e d o p t i c atrophy on t h e l e f t s i d e with r i g h t d i s c being normal. He was admitted f o r complete neuroendocrine workup a t t h i s time which showed a low Somatomedin-C l e v e l , subnormal growth hormone response t o arginine-glucagon s t i m u l a t i o n t e s t (maximum growth hormone l e v e l of 1.2 ng/ml), subnormal TSH response t o TRH s t i m u l a t i o n (maximum TSH l e v e l of 5AIIUIml) and a normal metyrapone t e s t . Serum LH and FSH were 7 a n d L l MIU/ml r e s p e c t i v e l y . Urinary s p . g r . and o s m o l a l i t y were w i t h i n normal l i m i t s i n d i c a t i n g normal p o s t e r i o r p i t u i t a r y f u n c t i o n s . CT s c a n of t h e head showed s m a l l o l d i n f a r c t i n r i g h t o c c i p i t a l l o b e with s l i g h t l y prominent CSF space. The bone age was compatible with h i s h e i g h t age. Subsequently, p a t i e n t has been s t a r t e d on Human Growth Hormone and levo-thyroxine treatment and response has been s a t i s f a c t o r v . These r e s u l t s i n d i c a t e h v~o~i t u i t a r i s m and o v t i c ,. .
atrophy following Reye's Syndrome. These complications a f t e r Reye's Syndrome have n o t been r e p o r t e d b e f o r e . The p a t i e n t s with Reye's Syndrome should be monitored f o r subsequent growth f a i l u r e and v i s u a l complications.
GROWTH HORMONE (hGH) THERAPY AND TUMOR RECURRENCE OF CHILDREN WITH BRAIN NEOPLASMS AND HYPOPITUITARISM.
407 s i l v a A. Arslanian, Dorothy J . Becker, P e t e r A. Lee, Allan L. Drash, Thomas P. Foley, J r . , U n i v e r s i t y of P i t t s b u r g h , School of Medicine, Department of P e d i a t r i c s , P i t t s b u r g h , PA W e r e p o r t on 34 c h i l d r e n (17 males, 17 females) with b r a i n tumors, i n c l u d i n g craniopharyngiomas ( l a ) , germinomas ( 4 ) , a s t r ocytomas ( 3 ) , chromophobe adenomas ( 3 ) , medulloblastomas (2) , glioma ( I ) , dermoid ( I ) , retinoblastoma ( I ) , and m e t a s t a t i c rhabdomyosarcoma from t h e p e l v i s ( 1 ) . A t t h e i n i t i a t i o n of tumor therapy, which c o n s i s t e d of s u r g e r y with and without radiotherapy, mean age was 9.3 y r s . (0.4-17.8 y r s ) . Post tumor therapy, 94% of t h e p a t i e n t s were G H d e f i c i e n t . 24/34 p a t i e n t s received hGH. Annual growth r a t e b e f o r e and a f t e r 1 y r . of hGH was 1 . 9 s . 7 cm/yr and 5.652.8 cm/yr, r e s p e c t i v e l y . 11 p a t i e n t s had 12 r e c u r r e n c e s . 8 of 24 r e c e i v i n g hGH had r e c u r r e n c e of tumor w i t h i n 0.5-36 mos.; 16 were tumor-free 8-72 mos. a f t e r i n i t i a l therapy. P a t i e n t s w i t h tumor r e c u r r e n c e had a markedly lower annual growth r a t e during t h e f i r s t y e a r of hGH than t h o s e without r e c u r r e n c e (mean 3.5k1.3 cm/yr v s 6.222.5 cmlyr, p<0.01). 3/11 p a t i e n t s with r e c u r r e n c e had n o t received hGH therapy; however, 1 was r e c e i v i n g I M t e s t o s t e r o n e monthly.
In conclusion, 24 of 34 p a t i e n t s with b r a i n tumors and hypop i t u i t a r i s m received hGH therapy. 8/24 (33%) had tumor r e c u r r e n c e , compared t o 3/10 (30%) who did not r e c e i v e hGH, and 1/10 who was r e c e i v i n g t e s t o s t e r o n e . The d a t a suggest t h a t hGH therapy i s not a s s o c i a t e d w i t h increased r a t e of tumor recurrence.
